Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy - Poll - MDSpire

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

  • By

  • Danai Dima

  • Al-Ola Abdallah

  • James A. Davis

  • Hussein Awada

  • Utkarsh Goel

  • Aliya Rashid

  • Shaun DeJarnette

  • Faiz Anwer

  • Leyla Shune

  • Shahzad Raza

  • Zahra Mahmoudjafari

  • Louis Williams

  • Beth Faiman

  • Joseph P. McGuirk

  • Craig S. Sauter

  • Nausheen Ahmed

  • Jack Khouri

  • Hamza Hashmi

  • May 31, 2024

  • 0 min

Share

Original Source(s)

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

  • by Danai Dima, Al-Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi

  • May 31, 2024

Related Content

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders

A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias